Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 6/2013

01.06.2013 | Original Paper

Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma

verfasst von: Krishna Pillai, Mohammad Hossein Pourgholami, Terence C. Chua, David Lawson Morris

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Malignant peritoneal mesothelioma (MPM) is a rare and fatal cancer. Females are found to survive longer than males after treatment, suggesting a possible involvement of hormonal factors. Estradiol is involved in cellular proliferation of a number of cancers and acts mainly through oestrogen receptors (ERs). Hence, we examined the expression of oestrogen receptors with correlation to prognosis.

Methods

Oestrogen receptors expression was examined using immunohistochemistry on 42 paraffin-embedded sections of MPM tumours. Kaplan–Meier survival curves were analysed to determine the significance of ER expression in relation to prognosis.

Results

ER-β (nuclear) was detected in 33 (79 %) patients. ER-β was also detected in the cellular cytoplasm of 9 (21 %) patients. Presence of ER-β (nuclear) was associated with favourable survival (univariate analysis, P = 0.001), whereas the presence of ER-β (cytoplasm) was associated with a poor survival (P = 0.014). Multivariate Cox regression analysis revealed the absence of ER-β (nuclear) and the presence of ER-β (cytoplasm) to be independent predictive factors for poor disease outcome (hazard ratio 5.4, 95 % confidence interval 1.86–15.75; P = 0.002 and hazard ratio 8.0, 95 % confidence interval 1.8–34; P = 0.005), respectively. ER-α (nuclear) was detected in only 4 (9 %) of patients and not statistically significant (univariate analysis, P = 0.066).

Conclusion

The presence of ER-β (cytoplasm) is associated with poor prognosis. The favourable survival association observed in patients with ER-β (nuclear) raises a question about the molecular mechanisms of the tumorigenic roles of ER-β in each cellular compartment and requires further studies.
Literatur
Zurück zum Zitat Acherman YI, Welch LS, Bromley CM et al (2003) Clinical presentation of peritoneal mesothelioma. Tumori 89:269–273PubMed Acherman YI, Welch LS, Bromley CM et al (2003) Clinical presentation of peritoneal mesothelioma. Tumori 89:269–273PubMed
Zurück zum Zitat Ahmed I, Koulaouzidis A, Iqbal J et al (2008) Malignant peritoneal mesothelioma as a rare cause of ascites: a case report. J Med Case Rep 2:121PubMedCrossRef Ahmed I, Koulaouzidis A, Iqbal J et al (2008) Malignant peritoneal mesothelioma as a rare cause of ascites: a case report. J Med Case Rep 2:121PubMedCrossRef
Zurück zum Zitat Allred DC, Harvey JM, Berardo M et al (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed Allred DC, Harvey JM, Berardo M et al (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed
Zurück zum Zitat Antman K, Shemin R, Ryan L et al (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 6:147–153PubMed Antman K, Shemin R, Ryan L et al (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 6:147–153PubMed
Zurück zum Zitat Baratti D, Kusamura S, Cabras AD et al (2010) Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 17:45–53PubMedCrossRef Baratti D, Kusamura S, Cabras AD et al (2010) Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 17:45–53PubMedCrossRef
Zurück zum Zitat Bechis SK, Carroll PR, Cooperberg MR (2011) Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 29:235–241PubMedCrossRef Bechis SK, Carroll PR, Cooperberg MR (2011) Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 29:235–241PubMedCrossRef
Zurück zum Zitat Cavallini A, Notarnicola M, Giannini R et al (2005) Oestrogen receptor-related receptor alpha (ERRalpha) and oestrogen receptors (ERalpha and ERbeta) exhibit different gene expression in human colorectal tumour progression. Eur J Cancer 41:1487–1494PubMedCrossRef Cavallini A, Notarnicola M, Giannini R et al (2005) Oestrogen receptor-related receptor alpha (ERRalpha) and oestrogen receptors (ERalpha and ERbeta) exhibit different gene expression in human colorectal tumour progression. Eur J Cancer 41:1487–1494PubMedCrossRef
Zurück zum Zitat Cheng J, Lee EJ, Madison LD et al (2004) Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 566:169–172PubMedCrossRef Cheng J, Lee EJ, Madison LD et al (2004) Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 566:169–172PubMedCrossRef
Zurück zum Zitat Chua TC, Yan TD, Morris DL (2009) Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol 99:109–113PubMedCrossRef Chua TC, Yan TD, Morris DL (2009) Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol 99:109–113PubMedCrossRef
Zurück zum Zitat Deraco M, Nonaka D, Baratti D et al (2006) Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 13:229–237PubMedCrossRef Deraco M, Nonaka D, Baratti D et al (2006) Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 13:229–237PubMedCrossRef
Zurück zum Zitat Deraco M, Baratti D, Cabras AD et al (2010) Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World J Gastrointest Oncol 2:76–84PubMedCrossRef Deraco M, Baratti D, Cabras AD et al (2010) Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World J Gastrointest Oncol 2:76–84PubMedCrossRef
Zurück zum Zitat Eltabbakh GH, Piver MS, Hempling RE et al (1999) Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 70:6–12PubMedCrossRef Eltabbakh GH, Piver MS, Hempling RE et al (1999) Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 70:6–12PubMedCrossRef
Zurück zum Zitat Harvey JM, Clark GM, Osborne CK et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481PubMed Harvey JM, Clark GM, Osborne CK et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481PubMed
Zurück zum Zitat Hayashi SI, Eguchi H, Tanimoto K et al (2003) The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 10:193–202PubMedCrossRef Hayashi SI, Eguchi H, Tanimoto K et al (2003) The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer 10:193–202PubMedCrossRef
Zurück zum Zitat Jassam N, Bell SM, Speirs V et al (2005) Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes’ staging. Oncol Rep 14:17–21PubMed Jassam N, Bell SM, Speirs V et al (2005) Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes’ staging. Oncol Rep 14:17–21PubMed
Zurück zum Zitat Kawai H, Ishii A, Washiya K et al (2005) Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 11:5084–5089PubMedCrossRef Kawai H, Ishii A, Washiya K et al (2005) Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 11:5084–5089PubMedCrossRef
Zurück zum Zitat Kinoshita Y, Takasu K, Yuri T et al (2013) Two cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohistochemical features. Ann Diagn Pathol 17:99–103PubMedCrossRef Kinoshita Y, Takasu K, Yuri T et al (2013) Two cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohistochemical features. Ann Diagn Pathol 17:99–103PubMedCrossRef
Zurück zum Zitat Lamont KR, Tindall DJ (2011) Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 25:897–907PubMedCrossRef Lamont KR, Tindall DJ (2011) Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 25:897–907PubMedCrossRef
Zurück zum Zitat Leung YK, Lam HM, Wu S et al (2010) Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer 17:675–689PubMedCrossRef Leung YK, Lam HM, Wu S et al (2010) Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer 17:675–689PubMedCrossRef
Zurück zum Zitat Liu MM, Albanese C, Anderson CM et al (2002) Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277:24353–24360PubMedCrossRef Liu MM, Albanese C, Anderson CM et al (2002) Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277:24353–24360PubMedCrossRef
Zurück zum Zitat Manzini Vde P, Recchia L, Cafferata M et al (2010) Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 21:348–353PubMedCrossRef Manzini Vde P, Recchia L, Cafferata M et al (2010) Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 21:348–353PubMedCrossRef
Zurück zum Zitat Merrill RM, Bird JS (2002) Effect of young age on prostate cancer survival: a population-based assessment (United States). Cancer Causes Control 13:435–443PubMedCrossRef Merrill RM, Bird JS (2002) Effect of young age on prostate cancer survival: a population-based assessment (United States). Cancer Causes Control 13:435–443PubMedCrossRef
Zurück zum Zitat Neumann V, Muller KM, Fischer M (1999) Peritoneal mesothelioma–incidence and etiology. Pathologe 20:169–176PubMedCrossRef Neumann V, Muller KM, Fischer M (1999) Peritoneal mesothelioma–incidence and etiology. Pathologe 20:169–176PubMedCrossRef
Zurück zum Zitat Niikawa H, Suzuki T, Miki Y et al (2008) Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 14:4417–4426PubMedCrossRef Niikawa H, Suzuki T, Miki Y et al (2008) Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 14:4417–4426PubMedCrossRef
Zurück zum Zitat Peng B, Lu B, Leygue E et al (2003) Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol 30:13–29PubMedCrossRef Peng B, Lu B, Leygue E et al (2003) Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol 30:13–29PubMedCrossRef
Zurück zum Zitat Pinton G, Brunelli E, Murer B et al (2009) Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res 69:4598–4604PubMedCrossRef Pinton G, Brunelli E, Murer B et al (2009) Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res 69:4598–4604PubMedCrossRef
Zurück zum Zitat Sridhar KS, Doria R, Raub WA Jr et al (1992) New strategies are needed in diffuse malignant mesothelioma. Cancer 70:2969–2979PubMedCrossRef Sridhar KS, Doria R, Raub WA Jr et al (1992) New strategies are needed in diffuse malignant mesothelioma. Cancer 70:2969–2979PubMedCrossRef
Zurück zum Zitat Sugarbaker PH (2009) Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach. Expert Opin Pharmacother 10:1965–1977PubMedCrossRef Sugarbaker PH (2009) Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach. Expert Opin Pharmacother 10:1965–1977PubMedCrossRef
Zurück zum Zitat van Leeuwen BL, Pahlman L, Gunnarsson U et al (2008) The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region. Crit Rev Oncol Hematol 67:229–236PubMedCrossRef van Leeuwen BL, Pahlman L, Gunnarsson U et al (2008) The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region. Crit Rev Oncol Hematol 67:229–236PubMedCrossRef
Zurück zum Zitat Woo IS, Park MJ, Choi SW et al (2004) Loss of estrogen receptor-alpha expression is associated with hypermethylation near its ATG start codon in gastric cancer cell lines. Oncol Rep 11:617–622PubMed Woo IS, Park MJ, Choi SW et al (2004) Loss of estrogen receptor-alpha expression is associated with hypermethylation near its ATG start codon in gastric cancer cell lines. Oncol Rep 11:617–622PubMed
Zurück zum Zitat Wu CT, Chang YL, Shih JY et al (2005) The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 130:979–986PubMedCrossRef Wu CT, Chang YL, Shih JY et al (2005) The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 130:979–986PubMedCrossRef
Zurück zum Zitat Yan TD, Popa E, Brun EA et al (2006) Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 93:1536–1542PubMedCrossRef Yan TD, Popa E, Brun EA et al (2006) Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 93:1536–1542PubMedCrossRef
Zurück zum Zitat Yan TD, Brun EA, Cerruto CA et al (2007) Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 14:41–49PubMedCrossRef Yan TD, Brun EA, Cerruto CA et al (2007) Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 14:41–49PubMedCrossRef
Zurück zum Zitat Yonemura Y, Tsukiyama G, Miyata R et al (2010) Indication of peritonectomy for peritoneal dissemination. Gan To Kagaku Ryoho 37:2306–2311PubMed Yonemura Y, Tsukiyama G, Miyata R et al (2010) Indication of peritonectomy for peritoneal dissemination. Gan To Kagaku Ryoho 37:2306–2311PubMed
Metadaten
Titel
Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma
verfasst von
Krishna Pillai
Mohammad Hossein Pourgholami
Terence C. Chua
David Lawson Morris
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-013-1408-2

Weitere Artikel der Ausgabe 6/2013

Journal of Cancer Research and Clinical Oncology 6/2013 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.